{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:26:57Z","timestamp":1760984817836},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1097\/adm.0b013e31828ee8a2","type":"journal-article","created":{"date-parts":[[2013,4,27]],"date-time":"2013-04-27T12:15:21Z","timestamp":1367064921000},"page":"299-301","source":"Crossref","is-referenced-by-count":3,"title":["Pathological Gambling in X-Linked Dystonia Parkinsonism"],"prefix":"10.1097","volume":"7","author":[{"given":"Lim Shanhui","family":"Gillian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"14","key":"R1-13-20210126","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2174\/138161211796150774","article-title":"Psychopharmacological treatment in pathological gambling: a critical review.","volume":"17","author":"Achab","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"1","key":"R2-13-20210126","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.physbeh.2011.04.055","article-title":"Pathological behaviors provoked by dopamine agonist therapy of Parkinsons disease.","volume":"104","author":"Ahlskog","year":"2011","journal-title":"Physiol Behav"},{"issue":"6","key":"R3-13-20210126","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.parkreldis.2006.07.011","article-title":"Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinsons disease.","volume":"13","author":"Bandini","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"R4-13-20210126","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/WNF.0b013e31824d529b","article-title":"Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease.","volume":"35","author":"Bosco","year":"2012","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"R5-13-20210126","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0025-6196(11)60538-7","article-title":"Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease.","volume":"84","author":"Bostwick","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"R6-13-20210126","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/157488611794480016","article-title":"Aripiprazole-induced pathological gambling: a report of 3 cases.","volume":"6","author":"Cohen","year":"2011","journal-title":"Curr Drug Saf"},{"issue":"9","key":"R7-13-20210126","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease.","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol"},{"issue":"4","key":"R10-13-20210126","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1468-1331.2008.02081.x","article-title":"Medications used to treat Parkinsons disease and the risk of gambling.","volume":"15","author":"Imamura","year":"2008","journal-title":"Eur J Neurol"},{"key":"R11-13-20210126","first-page":"603631","article-title":"Dopamine agonists and pathologic behaviors.","volume":"2012","author":"Kelley","year":"2012","journal-title":"Parkinsons Dis"},{"issue":"5","key":"R12-13-20210126","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00023210-200822050-00004","article-title":"Antiparkinsonian medication and pathological gambling.","volume":"22","author":"Lader","year":"2008","journal-title":"CNS Drugs"},{"issue":"9","key":"R13-13-20210126","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jocn.2008.12.010","article-title":"Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinsons disease.","volume":"16","author":"Lim","year":"2009","journal-title":"J Clin Neurosci"},{"issue":"12","key":"R14-13-20210126","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/mds.23177","article-title":"Clozapine for medication-related pathological gambling in Parkinson disease.","volume":"25","author":"Rotondo","year":"2010","journal-title":"Mov Disord"},{"issue":"5","key":"R15-13-20210126","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/jnnp.2006.102061","article-title":"Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease.","volume":"78","author":"Smeding","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"R16-13-20210126","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/mds.20501","article-title":"Addiction in Parkinsons disease: impact of subthalamic nucleus deep brain stimulation.","volume":"20","author":"Witjas","year":"2005","journal-title":"Mov Disord"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0b013e31828ee8a2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:08:30Z","timestamp":1620943710000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01271255-201307000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0b013e31828ee8a2","relation":{},"ISSN":["1932-0620"],"issn-type":[{"value":"1932-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}